This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Rehabilitation of erectile function following radical prostatectomy
Andrew R. McCullough
Department of Urology, New York University School of Medicine New York, NY 10016, USA
Abstract
The concept of muscle rehabilitation after nerve injury is not a novel idea and is practiced in many branches of
medicine, including urology. Bladder rehabilitation after spinal cord injury is universally practiced. The erectile
dysfunction (ED) experienced after radical prostatectomy (RP) is increasingly recognized as being primarily
neurogenic followed by secondary penile smooth muscle (SM) changes. There is unfortunately no standard approach to
penile rehabilitation after RP because controlled prospective human studies are not available. This article reviews the
epidemiology, experimental pathophysiological models, rationale for penile rehabilitation, and currently published
rehabilitation strategies. (Asian J Androl 2008 Jan; 10: 61_74)
Keywords: erectile dysfunction; penile rehabilitation; radical prostatectomy
Correspondence to: Andrew R. McCullough, MD, FACS, Department of Urology, New York University School of Medicine, 150 East
32nd Street, 2nd floor, New York, NY 10016, USA.
Tel: +1-646-825-6311 Fax: +1-646-825-6397
E-mail: andy.mccullough@nyumc.org
DOI: 10.1111/j.1745-7262.2008.00366.x
1 Introduction
Prostate cancer is the most common type of solid cancer affecting American males [1]. According to the American
Cancer Society, there were approximately 232 000 newly diagnosed cases diagnosed in the United States in 2005
(American Cancer Society Surveillance Research, 2005). The incidence of prostate cancer appears to be increasing
worldwide, and is the second leading cause of cancer death in the US, with estimates of over 30 000 deaths during
2005. Men are diagnosed at increasingly younger ages. On the positive side, the 10-year survival rate is estimated to
be as high as 92%. This high survival rate means that men will be living for a longer period of time with side effects
that develop as a result of treatment.
Curative treatment of localized prostate cancer includes radiation therapy and radical prostatectomy (RP), with
roughly equal numbers seeking each therapy. RP is
the most common treatment for localized prostate cancer, with over
60 000 men undergoing RP every year [2].
Sexual dysfunction is the most common long term complication from
surgery. The sexual dysfunction, encompasses universal loss of ejaculation, erectile dysfunction (ED), decreased
orgasmic pleasure and diminished libido. The reported incidence of ED after RP varies from study-to-study,
depending upon the age of the patient, erectile function prior to surgery, pre-exisiting medical conditions, the nature of the
operation (i.e., nerve-sparing, unilateral or bilateral), and the experience of the surgeon.
It is important to understand the prevalence of ED in the population before undergoing RP and cover realistic
outcomes in this regard. There have been numerous reports on the prevalence of ED in the elderly population.
However, the occurrence of ED in healthy men without prostate cancer participating in prostate cancer screening
programs has been poorly studied. Knowing the prevalence of ED in this group is important because it can be used as
a baseline to determine the incidence of ED caused by prostate cancer and its related treatments. In a multinational
study, 1 273 men without prostate cancer completed the International Index of Erectile Function (IIEF) questionnaire
[3]. The mean age of this cohort was 57.6 years (range, 40_56 years) and 50.1% reported some ED. Of the men in
this cohort, 8.8% had mild ED, 10.4% had mild-to-moderate ED, 9.4% had moderate ED, and 21.7% had severe ED.
Older age (> 56 years), lower socioeconomic class, income, and education, and absence of a partner were all
statistically more common in men with ED. The fact that 20% of men had severe ED in this older age group should
be kept in mind when analyzing erectile function status
in prostate cancer patients.
Penson et al. [4] reported that, while 81% of
post-RP participants indicated that they had erections firm
enough for intercourse prior to surgery, only 9% had
strong erections 6 months after surgery. By 60 months
after surgery, 55% of men reported an inability to achieve
any erections and only 28% of the subjects reported
erections sufficient for intercourse. The degree of sexual
bother decreased over the 5-year period with 46%
indicating that sexual function was a moderate or major
problem at the end of this interval. It is unclear whether the
decrease in sexual bother was due to improved function
or resignation and acceptance of their ED. Other studies
have reported ED rates after surgery of 50%_80%
[5_8], while Kendirci and Hellstrom [9], in a review on
management of ED after RP, reported an incidence ranging
between 16% and 82%.
The introduction of the nerve sparing RP
(NSRRP)[10] has improved postoperative results, but there
remains tremendous variation in published rates of
preservation of erectile function. The discrepancy between
the reported preservation of nerves and recovery of
erectile function leads to several important questions. What
is the mechanism for ED after RP? Are the nerves damaged? Do we truly identify all the nerves at the time
of RP? Since the time course of recovery is consistent
with nerve regeneration or repair, can something be done
to enhance neural regeneration? Is something else being
damaged during surgery? Is there arterial injury? Does
a secondary cavernosal smooth muscle (SM) injury
occur from the nerve injury? Is the ED a result of corporal
hypoxia? What is the benefit of penile rehabilitation after
injury that occurs due to the surgery? If so, what kind,
and when should it be started?
Many of these questions remain unanswered despite
a history of over 100 years for this curative surgery for
prostate cancer [11]. It is beyond the scope of this
article to address all these questions. The need for erectile
rehabilitation is being increasingly recognized. The
concept of end-organ rehabilitation after nerve injury is not
foreign to the urologist. Urologists have been
rehabilitating neurogenic bladders after spinal cord injury for over
40 years. Yet, there is no standard penile rehabilitation
protocol after RP similar to bladder rehabilitation or muscle
rehabilitation after any injury in other areas of the body.
This article will limit its review to the experimental and
clinical literature on rehabilitation of erectile function
after cavernous nerve injury in an animal model and radical
surgery in the human.
2 ED after NSRRP: the problem
Why doesn't this consensus exist? There are many
reasons but foremost was the lack of uniform acceptance that the problem even exists. With initial reports of
postoperative "potency" rates in excess of 90% [12],
ED post-RP was blamed on poor surgical technique and
inexperience. RP is now one of the most commonly performed open procedures during urologic residency
and it has become apparent that many factors are
involved in a successful erectile outcome after surgery:
preoperative, intraoperative and postoperative issues.
In order to address a problem it has to be defined,
recognized, and accepted. Until 1992 and the National
Institute of Health (NIH) consensus position paper on
ED, there was no uniformly accepted definition of ED
[13]. Many of the papers on post RP ED before and
after 1992 did not use uniform or standard definitions or
validated questionnaires in reporting their rates of
erectile function preservation [14_17]. The first simple and
validated questionnaire to be used by urologists was first
introduced by O'Leary in 1995 [18]. Krupski [19]
reported a high level of variation in erectile function rates
depending on the specific definition used. In a
longitudinally followed cohort of 260 patients, whereas only 5%
of men described their erections firm enough for
intercourse reported, 61% rated their ability to function
sexually as good or very good [19]. As more standardized
definitions are used, reported erectile function
preservations rates have decreased [4, 20]. To add to the
confusion, current erectile function rates include men
successfully using phospodiesterase 5 inhibitors
(PDE-5i), who by definition have some form of ED. Very few men claim
erectile function is as good postoperatively as it was
preoperatively and virtually none are better off.
3 Mechanism of erection
Penile erection is a neurovascular event that depends
on relaxation of trabecular and vascular SM in the
corpora cavernosa and corpus spongiosum. During the
flaccid state the SM of the trabeculae in these tissues and in
the blood vessels of the penis are contracted and blood
flow is reduced. Tumescence depends upon SM relaxation mediated by cholinergic and non-adrenergic
non-cholinergic (NANC) mechanisms involving the release
of nitric oxide (NO) and other mediators, which
stimulate production of the intracellular cyclic GMP [21]. This
second messenger causes SM relaxation through a
variety of mechanisms, including reduction of intracellular
calcium [22]. The vasodilator prostaglandin E1
(PGE-1) also causes SM relaxation but by increasing the
concentration of the cyclic AMP via stimulation of adenylate
cyclase [23, 24]. The end result again is a decrease in
intracellular calcium. In either case, relaxation of
corporal SM occurs, resulting in rapid arterial filling and
engorgement of the sinusoids within the cavernosal, as well
as veno-occlusion, which results from compression of the
subtunical venules against the tunica albuginea (Figure 1).
Synthetic exogenously administered PGE-1(alprostadil)
reproduces the hemodynamic effects observed in a natural
erection. The vasodilatory effects of alprostadil on the
cavernosal arteries and the trabecular SM of the corpora
cavernosa result in rapid arteriolar inflow and expansion
of the lacunar space within the corpora. As the expanded
corporal sinusoids are compressed against the tunica
albuginea, venous outflow through the subtunical
vessels is impeded and penile rigidity develops. The fact
that alprostadil has a direct vasodilatory effect on SM in
the penis is the basis for its efficacy in the treatment of
non-nerve-sparing or nerve-sparing post-RP ED, where
nerve damage prevents the normal erectile stimulus from
occurring. By improving blood supply to the damaged
tissues, healing may occur and can be considered
rehabilitative.
4 Animal models of cavernous nerve injury
In 1983 Lue and associates [25] described an animal
model that closely approximates the effect of RP. The
cavernous nerves in the dog are readily visible as
discrete nerve trunks coursing postero-laterally to the
prostate. As the prostate is an intra-abdominal organ, its
removal with nerve preservation is relatively easy. The
acute (three dogs) and chronic (three dogs) effects of
canine RP on erectile function was investigated. Acutely,
all dogs responded to nerve stimulation after
prostatectomy, equally to unilateral or bilateral nerve
stimulation, but failed to respond after complete nerve transaction. In the
chronic dogs (two months), one dog lost erectile
function acutely and all dogs lost their erectile response by 2
months. This study supports the concept that unilateral
nerve stimulation is sufficient for an erectile response
and ED can develop over time after prostatectomy, without
transaction of the nerves. These observations
corroborate the anectodal reports of men post-RP describing
erections around their catheter but eventual complete loss
after catheter removal.
In 1991 Quinlan [26] examined the effect of bilateral
nerve ablation and genito-femoral nerve grafting, in
effect grafting a peripheral nerve to an autonomic nerve.
The results were effective restoring vaginal intromission
after electrically induced erections in rats with bilateral
nerve ablation after grafting. There was a notable
time-dependent return of function consistent with nerve
regrowth (Table 1).
In 1995 Carrier and associates [27] demonstrated
the pacute loss (3 weeks) of erectile function and nitric
oxide synthase (NOS) staining in the cavernous nerves
of rats undergoing unilateral and bilateral cavernous nerve
ablation. At 6 months the unilateral group regained
function and NOS containing nerves, whereas the bilaterally
ablated group had absolutely no return of erectile
function or NOS staining.
In 1997 Klein [28] attempted to characterize the early
molecular events after penile denervation and to
investigate whether cavernous nerve injury causes apoptosis.
He utilized a rat model of penile denervation in which
penectomy was performed at specific time intervals
after nerve damage. DNA was extracted for DNA
fragmentation studies, tissue was stained for apoptotic nuclei,
and mRNA was analyzed on a northern blot for sulfated
glycoprotein-2 (SGP-2) expression. SGP-2, also known
as clusterin, is a gene product that has been postulated to
play a role in programmed cell death and its induced
synthesis has been shown to accompany apoptosis in many
urogenital tract sytems [29]. Clusterin analysis was done
on five groups of three rats undergoing cavernous nerve
injury followed by penectomy at days 1, 2, 3, 6 and 10
with a control group of 15 rats undergoing sham surgery.
DNA fragmentation was employed using in
situ end labeling (ISEL) on a separate group of rats at day 2.
DNA fragmentation and condensed cell nuclei characteristic of apoptotic cells were seen in the glans penis
and the corporal bodies. However, the erectile tissue
nuclei of sham operated controls did not stain and there
was no evidence of apoptosis in any cells.
Figure 2 demonstrates the concomitant increase in
clusterin in the neurectomized animals versus the sham
group in the first two days, returning to sham levels at
day 10 [28]. Clusterin levels have an increased
expression in the rat ventral prostate after castration, in the rat
kidney after vascular injury or unilateral obstruction, and
in the cavernous tissue of castrated rats. This was the
first animal study to experimentally support the concept
of post cavernous nerve ablation induced penile apoptosis
and the clinical phenomenon of decreased penile size
after RP. Human longitudinal and cross sectional studies
have shown significant loss of stretched penile length as
early as one week post-RP [30_32].
The results by Klein were supported by User et
al. [33] using a rat model of unilateral and bilateral nerve
ablation. Penile weight, DNA content, total protein
content, were measured at days 7,14, 28 and 60. An
apoptotic index was measured at days 1, 2, 7, 14, 28 and
60. In the bilateral nerve ablation group there was a
significant decrease in penile weight at all time points
between 7 and 60 days and a decreased DNA content after day 14. In the unilateral group, weight changes
were observed at day 60 without any significant changes
in DNA at any time. Significant apoptosis was seen as
early as day 1 until day 28, even in the unilateral group.
The corporal cells staining most intensely for apoptosis
were those directly under the tunica albuginea. This may
be significant in view of the recognized increased
incidence of Peyronie's disease in men after RP [34] and the
loss of stretched penile length after RP.
In order to attenuate apoptic and functional changes
that occur after nerve injury, Burnett et
al. [35, 36] demonstrated the benefit of the neuroprotective molecule,
FK506, administered before and after the nerve injury.
Immunohistochemical and erectile function testing
demonstrated preserved cavernous tissue histology and
erectile function in immunophilin ligand treated rats. Such
encouraging results were unfortunately not witnessed in
human placebo controlled trials with FK506 [37].
Rajfer et al. [38, 39] examined the effect of sildenafil
and vardenafil administration after bilateral cavernous
nerve ablation (BCNA). Both studies demonstrate a
benefit from PDE-5i administration after cavernous nerve
ablation in preventing cavernous SM fibrosis and
preventing corporal veno-occlusive dysfunction. These
investigations hypothesized that PDE-5i increased SM cell
replication through increased intracellular cGMP
concentration and inducible NOS (iNOS) upregulation.
Vigozzi et al. [40] demonstrated penile hypoxia,
fibrosis, PDE-5 down regulation, resistance to tadalafil,
sodium nitroprusside hypersensitivity and loss of penile
NO, neuronal NOS (nNOS), endothelial NOS (eNOS), after BCNA in rats at 3 months. Chronic tadalafil
administration reversed all these findings except the loss of
penile NO, eNOS and nNOS. iNOS was not measured.
McVary and associates [41] showed that the decreased sonic hedgehog protein (SHH) signaling (derived
from the cavernous nerves) is the cause for penile
morphologic changes after cavernous nerve injury. The SHH
signaling pathway is critical for establishing embryologic
sinusoid morphology of the corpora cavernosa, and
continues to regulate and maintain penile morphology in the
adult organ [42]. In two rat models of ED, the diabetic
bio-breeding/worcester rat (BB/WOR) and in the cavernous nerve (CN)-injured Sprague Dawley rat, SHH
protein was significantly decreased [43]. In these same
models there are significant morphological changes in
the corpora cavernosa, including increased apoptosis and
decreased SM and endothelial staining [42, 43]. In an
elegant series of experiment these investigators
demonstrated that SM and endothelial apoptosis in the
cavernous nerve injury rats were similar to that induced in
non neurectomized rats given an SHH inhibitor. Here
they establish reversibility of the penile apoptosis in
normal rats given a short term course of intrapenile SHH
inhibitor and prevention of apoptosis by the
administration of SHH at the time of cavernous nerve injury. They
suggest a role for intrapenile SHH administration in the
prevention of penile cavernous SM and endothelial apoptosis while the nerves are recovering after injury.
In summary, these animal studies demonstrate that
cavernous nerve injury can occur with manipulation
alone, cavernous nerve regeneration does occur, nerve
grafts can be effective after nerve transaction, penile
shrinkage and cavernous SM fibrosis occurs after nerve
injury, and the administration of neuroprotective agents,
PDE-5i or SHH protein can decrease or prevent
cavernous SM fibrosis and preserve erectile function in
neurectomized rats.
5 Nerve damage in post-RP ED
The etiology of ED after surgery for prostate cancer
is likely multifactorial. Prostate cancer strikes men in
their seventh decade of life when many are already
experiencing ED [44]. While pre-surgical erectile function is
a significant factor in determining erectile function after
surgery [45] other invoked mechanisms include
vascular injury and nerve injury [12]. The role of arterial injury
as a cause of ED is unclear. In a large series of
preoperatively potent men with postoperative ED undergoing
penile dopplers after RP the incidence of arterial injury was
less than 10%. In men with no arterial disease the most
common finding was veno-occlusive dysfunction [46].
For this reason, one can postulate an initial neurogenic
injury as the most likely initial cause of post RP ED.
Damage to the nerves after cavernous nerve injury
and prostate reduces the amount of nNOS and NO that
can be released during sexual activity, thereby reducing
erectile function [27]. Consistent with the importance of
surgical technique, there appears to be an advantage to
nerve sparing over non nerve sparing ablation and
bila-teral to unilateral nerve ablation. Gralnek
et al. [47] reported on 129 men who responded to a questionnaire,
83 of who had non NSRRP (NNSRRP) and 46 of who had a unilateral NSRRP (UNSRRP). The sexual
function score, which included questions regarding
spontaneous erections and the use of erectile aids, showed a
statistically significant difference in sexual function in
men with a unilateral vs. a non nerve sparing surgery.
In a series of almost 3 500 men Kundu et
al. [48] reported erections sufficient for intercourse in 76% of
preoperatively potent men treated with bilateral NSRRP
(BNSRRP) and 53% of men with UNSRRP. In men less than 70 years of age the response rates were 78% and
53%, respectively. This series unfortunately
retrospectively included men from 1983, prior to standardized ED
questionnaires, and men currently taking
PDE-5i.
These data suggest that preservation of local nerves
is important for maintenance of erectile function.
Decreased or loss of inervation within the erectile tissues
has a number of deleterious effects; it prevents the
release of NO from NANC nerves; decreases the
production of cyclic nucleotides within the vascular SM; and
reduces the subsequent relaxation of these tissues. As a
result the intermittent increased blood flow and
tumescence that would normally occur during nocturnal penile
tumescence (NPT) or sexual stimulation is abolished or
greatly diminished.
To complicate the question of nerve preservation,
the exact location of the nerves that need to be preserved
has recently been brought into question [49]. In an MRI
study of men undergoing NSRRP performed by a single
surgeon, attempts were made to visualize the
neurovascular bundle (NVB) in men preoperatively. In 38% of
men the NVB were not visualized on MRI (Group 1) whereas 41% had the NVB clearly visualized (Group 3).
At 1 year there was almost a two-fold improvement in
Sexual Health Inventory for Men (SHIM) score in men
in whom the NVB was visualized. The percent change
from baseline SHIM score was 44% (8.2% to 19.7%) in
Group 1 and 24% (15.0% to 21.9%) in Group 2.
These findings were also seen when the men were
categorized by age greater or less than 60 years of age.
No systematic penile rehabilitation was used in any of these
men. Though the results were statistically significant,
obviously missing is histologic documentation that the
structures seen on MRI were the NVB responsible for
penile erections. Not reported was the ability to have
erections satisfactory for sexual function.
6 NPT after RP
Data on NPT testing after RP are inconsistent and
contradictory. Bannowsky [50] described 70% axial
rigidity for 10 min in 17 out of 18 men at 15 days from
surgery after NSRRP. This is consistent animal data
and anecdotal experience of men having erections around
their catheter postoperatively.
Kawanishi [51] described nine out of 21 (42%) with
normal NPT at 4_6 weeks, as defined by an increase in
diameter of > 20 mm for at least 5 min.
In a retrospective self selected group of 11 potent
patients after RP, Lerner [52] reported that only two were
mostly satisfied with their sex life according to a
validated quality of life questionnaire. Rigiscan testing
revealed that eight of the 11 patients had nocturnal
erections which were adequate for vaginal penetration. Three
of the five patients, who stated that they were mostly
dissatisfied with their sexual functioning, had objective
evidence of adequate erectile ability as documented by
Rigiscan. Three of the four patients who were
ambivalent with respect to their sexual function also
demonstrated objective evidence of normal erectile function.
Lacking in all the previous small series was exact
quantification of the nocturnal tumescence and statistical
analysis.
In a retrospective comparative study of men with
non surgical and surgical ED by Fraiman [53] a
significant and profound loss of nocturnal erections was seen
in men after RP at an average time from surgery of 9
months. In a prospective longitudinal 12-month NPT
study of fully sexually functional men pre and one month
post operatively, NPT was virtually eliminated [54]
(Table 2). Follow-up with serial NPT testing
demonstrated a time dependent return of NPT with the biggest
improvement occurring 16 weeks post operatively [55]
(Figure 3, personal data). Figure 4 (personal data)
demonstrates the actual scan of a man preoperatively and
post-operatively.
6.1 Penile hypoxia after RP
During erection, oxygen tension changes in the
corpus cavernosum penis from 25_40 mmHg in the flaccid
state to 90_100 mmHg in the erect state. There are acute
and chronic effects of chronic hypoxia. Oxygenation of
the cavernous tissue is an important factor in the
regulation of local mechanisms of erection. Arterialized blood
flow during nocturnal erections is believed important to
provide the oxygen necessary for the formation of NO
by both nNOS and eNOS. NO after crossing into the
SM cell reacts with guanylate cyclase to catalyze the
conversion of GTP to GMP. The lack of free oxygen,
transported to the penis by oxygenated hemoglobin,
diminishes the synthesis of NO and cGMP formation. Poor
oxygenation stimulates TGF-β and results in a
predisposition to cavernous fibrosis by increased synthesis of
collagen [56]. Increased collagen deposition is caused
by decreased corporal oxygenation or hypoxia [57].
Cavernous neurotomy was demonstrated to produce hypoxia and fibrosis in rat corpus cavernosum [28, 56,
58]. In this study, ablation of cavernous nerves
bilaterally was associated with increased TGF-β1 mRNA
expression and hypoxia-inducible factor-1α, TGF-β1 and
collagen I and III protein expression. It was theorized
that strategies that improve corporal hypoxia might
benefit erectile function after RP. Treatment of human
corpus cavernosum SM cells with TGF-β1 increased
collagen synthesis [59]; this increase in collagen was
attenuated by simultaneous administration of PGE-1. In addition
PGE-1 suppressed TGF-β1 induction of TGF-β1 mRNA.
Kim et al. [60, 61] showed that isolated human and
rabbit corpus cavernosum tissue strips exposed to
arterial-like pO2, relaxed with acetylcholine and to electrical
stimulation of the autonomic nerves. Decreasing
pO2 to levels measured in the flaccid state resulted in a diminishing
relaxation response. Normoxic conditions readily restored
endothelium-dependent and neurogenic relaxation.
In the rabbit corpus cavernosum, low
pO2 reduced basal levels of cGMP and prevented cGMP accumulation induced by
electrical stimulation and similarly inhibited NOS activity
in corpus cavernosum cytosol tissue [60, 61].
Blood gas studies in human models have revealed
decreased oxygen tension in vasculogenic impotence and
hypoxia in the flaccid penis. Corporal and penile flaccid
oximetry was examined in a cross sectional comparative
study of 101 men (22 potent, 36 non-RP ED, and 32 RP
ED). Although there was no significant difference in
StO2 among ED patients, RP ED patients have significantly
lower corporal StO2 than potent patients (Table 3) [62].
Histomorphological studies in men after RP suggest
there are changes in cavernous SM and collagen content
[63]. As soon as two months after RP surgery,
trabecular elastic fibers and SM fibers were decreased, and
collagen content was increased, and these changes were
accentuated after one year. This fibrosis is believed to
have both denervation and ischemic etiologies. ED after
RP is often associated with increased cavernous fibrosis
and allows us to consider programs of regular corporal
oxygenation with intracorporal PGE-1 to reduce
postoperative ED [64].
7 Penile rehabilitation
7.1 Vacuum erection device (VED)
The VED is a longstanding effective erectogenic aid.
Though the effectiveness with ED is unquestionable, its
role in penile rehabilitation is unclear. It is known that a
proximal constriction band causes some penile ischemia
while in use [65, 66]. The inflow of blood becomes non
arterial and there is no SM relaxation [67].
In a randomized prospective study of 109 patients
both nerve sparing (NS) and non-NS (NNS), 74 patients
were instructed to apply the VED daily for 9 months
vs. 35 men with no treatment. The duration of the VED
application was not specified though the constriction band
was used only for intercourse. Sixty of the 74
completed the VED arm. Men and their partners were mailed
questionnaires. The results were inconclusive as 19/60
(32%) of the VED group reported spontaneous erections
and 10/60 (17%) reported vaginal penetration (Table 4)
[68]. In the "no treatment" group, 13/35 (37%) reported
spontaneous erections and 4/35 (11%) reported erections
satisfactory for vaginal penetration. The VED men stated
subjectively that they had less penile shrinkage, but no
objective measurements were made. 76%_86% of men were able to have sexual intercourse with the vacuum
device regardless of the nature of the NS surgery. No
long term follow-up or PDE-5 responsiveness was reported [68]. Though VED is effective in the treatment
of post RP ED it has not yet been proven to be effective
in penile rehabilitation protocols. That VED induces
corporal ischemia, acidosis and lack of SM relaxation may
theoretically be detrimental to longterm penile rehabilitation [69].
8 Intracavernosal alprostadil PGE-1 (ICT)
As indicated previously, PGE-1 induces erections by
directly stimulating the production of cyclic AMP within
the SM cells [23] and therefore does not require a
functioning nerve to induce SM relaxation. By contrast, oral
PDE-5is, which work by preventing the breakdown of
cyclic GMP [70] require the presence of a functional
nerves and NO to produce this second messenger and
hence facilitate erections. These latter agents are in theory
unlikely to be active until nerve function is at least
partially restored.
There is much support for the early use of
rehabilitative ICT [64]. At a time when surgical technique and
expertise and patient age were considered the prime
determinants of erectile function outcomes, this was the
first study to suggest that pharmacologic intervention
during the postoperative period could impact the results.
The study suffers from methodological flaws. Thirty
patients were randomized either tri-weekly ICT (Group
1) or no therapy (Group 2), starting one month after
surgery for a total of three months. They were then
evaluated after 3 months or at 4 months from surgery. Twelve
of the 15 ICT patients completed the study whereas all
15 of the observation group completed. The evaluation
consisted of a non-validated questionnaire, penile doppler
testing and three nights of nocturnal penile tumescence
testing. No preoperative testing was done, and no doppler
or NPT data were included in the article, only summary
data. The authors report erections satisfactory for
intercourse in 67% group 1 and 20% of group 2.
Contemporary placebo controlled studies using validated
questionnaire report much lower erectile function rates at 4
months. Normal penile hemodynamics were reported in
83% group 1 vs. 33% group 2. Veno-occlusive
dysfunction was seen in 17% of group 1 vs. 53% of group
2. NPT testing was "normal" in 58% of group 1 and 20%
of group 2. No clear definitions were made of normal
Doppler score or NPT testing. This early study was
completed in the pre-PDE-5 era when validated sexual
function questionnaires were not routinely used. Though
intuitively appealing the results need to be interpreted
cautiously as the results have yet to be duplicated in a
placebo controlled fashion or on a larger scale.
In a small non placebo controlled series of 22 men
initiated on ICT 2_3 times a week [71] and on immediate
nightly sildenafil 50 mg , at a mean follow-up of 6 months
(3_8 months), 50% of men reported weak spontaneous
erections, though none sufficient for intercourse (SHIM
score 8.1 ± 0.3). Ninety-six percent of the men were
sexually active with injection therapy or a combination, similar
rates to the VED. A deficiency of the study is its short term
follow-up and lack of a randomized non-treatment control
arm. The psychological benefit of being able to resume
earlier sexual intercourse is a positive attribute.
In a non randomized observational study of post-RP
men presenting for treatment with sildenafil refractory
ED, patients were either offered ICT rehabilitation (R)
(n = 58) or no rehabilitation (NR) (n
= 78) [72]. The men self selected their therapy. ICT was suggested
tri-weekly. Only patients who presented within 6 months
post RP, who completed the IIEF questionnaire, and who
had been followed for at least 18 months were included.
At 18 months post RP, there were statistically
significant differences between the two groups in the
percentage of patients who were capable of having
medication-unassisted intercourse (R = 52%
vs. NR = 19%); mean erectile rigidity (R = 53%
vs. NR = 26%); mean IIEF erectile function (EF) domain scores (R = 22
vs. NR = 12); the percentage of patients with normal EF domain
scores (R = 22% vs. NR = 6%); the percentage of
patients responding to sildenafil (R = 64%
vs. NR = 24%); the time to become a sildenafil responder (R = 9 ± 4
vs. NR = 13 ± 3 months); and the percentage of patients
responding to ICI (R = 95% vs. NR = 76%). Though
supportive of the concept of early penile rehabilitation,
this study suffers from a strong patient self selection
bias and lack of a placebo arm.
In support of early penile rehabilitation, the effects
of intracavernosal PGE-1 in men were examined in men
who had undergone an NNS RP. In this trial 36 patients
initiated treatment within three months of RP, and 37
received it beginning 4_12 months after surgery. Color
duplex Doppler ultrasound was conducted at various
points over 12 months after the operation. Patients who
initiated therapy within three months of surgery had a
significantly better erection grade and a higher peak
systolic velocity in at least one cavernosal artery, than those
who initiated treatment later. In addition those subjects
who received treatment the first month after surgery had
a better erectile response than those who started
receiving it 2_3 months after surgery. There was a higher
incidence of painful erections in the group initiating
treatment earlier [73]. In this author's opinion, due to the
perceived invasiveness of intracavernosal therapy, it is
difficult to convince patients to self inject frequently
enough to benefit from the penile injections in
rehabilitative fashion
9 Intraurethral alprostadil (IUA)
Costabile et al. [74] evaluated the erectile response
to intraurethral PGE-1 in 384 men with ED after RP,
with treatment beginning no less than three months after
surgery. This was a multi-institutional study before the
approval of PDE-5i and included both men at differing
times from surgery and with both NSRRP and
NNSRRP. Initial doses were 125 or 250 μg, which were tititrated
to 500 or 1 000 μg for adequate erectile response. When
treatment was administered in the clinic 70% of the
participants developed an erection sufficient for intercourse.
These subjects were then randomized to a 3-month
at-home trial with either PGE-1 or placebo. During this
phase 57% of the subjects had successful intercourse at
least once at home, compared to an intercourse rate of
6.6% of men treated with placebo. These rates compare
favorably with PDE-5i response rates in younger men
with BNSRRP. Adverse events included penile pain and
urethral pain/burning. This placebo controlled study
supports the use of a less invasive treatment modality in men
who would not otherwise respond to PDE-5i.
More recently Raina et al. [75] reported the results
of a study in 54 post-RP men who used transurethral
PGE-1 (250, 500 or 1 000 μg). Subjects experienced
ED for at least six months after surgery before initiating
treatment. Fifty-five percent of the subjects were able
to achieve and maintain erections sufficient for intercourse
while on treatment, and 48% continued long-term therapy
with a mean use of 2.3 years. There were no significant
differences in responses between those men who had a
NSRRP surgery (34 patients) and those who had a NNSRRP procedure (20 subjects).
A recent report demonstrated the efficacy of early
intervention with transurethral PGE-1 in men with
prostatectomy-associated ED [76]. In this nonrandomized
study 56 men who had a bilateral nerve-sparing
operation began treatment with 125 μg PGE-1 three times a
week within 4 weeks of surgery; another 35 men served
as an observational control group. Treatment was
continued for approximately 6 months, with the dose of
PGE-1 increased to 250 μg after six weeks. In the PGE-1 group
38 out of 56 men (68%) continued treatment for the
entire six months. At 6 months, 28 out of 38 men (74%)
resumed sexual activity; 15 (39%) had natural erections
sufficient for vaginal penetration without treatment, and
13 (34%) used PGE-1 as an erectile aid when having
intercourse. In the observation group 13 out of 35 men
(37%) resumed sexual activity, four (11%) had natural
erections sufficient for vaginal penetration, and nine
(25%) used adjuvant treatments. This encouraging but
nonrandomized small study suggests that post operative
transurethral PGE-1 is well tolerated and may be
beneficial in penile rehabilitation in the ED that accompanies
RP. The ability of PGE-1 to increase SM relaxation and
blood supply, even in the presence of local nerve trauma,
suggests that this agent may rehabilitate nerves and blood
vessels that receive damage during surgery.
One possible mechanism of nerve rehabilitation is
through cyclic AMP, which is reported to play a role in
regeneration in both the peripheral and central nervous
systems [77, 78]. In an in vitro model of axotomy using
adult retinal ganglion cell axons, increasing cyclic AMP
promoted growth cone regeneration under conditions
which normally would result in low regenerative
potential [79]. Cai et al. [80] demonstrated that endogenous
levels of cyclic AMP are higher in young neurons, which
are able to regenerate after injury, as compared to older
neurons, which lose the ability to regenerate.
Kogawa et al. [81] reported on nerve regeneration in
dorsal root ganglia (DRG) of diabetic rats. Prior to nerve
crush injury there were no apoptosis-positive DRG
neurons observed; subsequent to axonal injury,
apoptosis-positive neurons were seen in diabetic but not in
non-diabetic animals or in rats treated with a PGE-1 analog.
The regeneration distance at day 7 after injury was shorter
in diabetic rats than in animals in the other groups. The
cyclic AMP content of DRG on day 7 was higher than
that at day 0 in nondiabetic and PGE-1-treated animals,
whereas it was not increased after 7 days in diabetic
rats. The results of this investigation suggest that
PGE-1 is able to rescue DRG neurons from apoptosis and that it
improves axonal regeneration in diabetic rats.
The beneficial effect of PGE-1 on corporal
oxygenation has been demonstrated. In 101 patients with ED
the administration of PGE-1 intraurethrally or
intracorporally resulted in a 37_57% increase in corporal
oxygen saturation StO2 [82] (Table 5). The increase in
oxygenation occurred in the MUSE patients at a dose of 125 µg
and despite marginal tumescence (Table 5) [82]. Hence,
PGE-1 may not only rehabilitate penile function after a
RP by directly relaxing cavernosal SM, thereby
enhancing blood flow, but also may stimulate regeneration of
local nerves, thereby increasing NO release. Such a dual
mechanism of PGE-1 would shorten recovery time and
hasten the return of spontaneous erections and PDE-5
responsiveness. These results indicate that PGE-1 is able
to reverse some of the deleterious effects of RP that
result in ED. Further, it appears that the earlier after
surgery PGE-1 is initiated, the better the recovery of
erectile response. The ability of PGE-1 to directly induce
SM relaxation and increase blood supply, even in the
presence of local nerve trauma, as well as stimulate
regeneration of damaged nerves, suggests that this drug may
be pivotal in rehabilitating nerves and blood vessels that
have been traumatized.
10 PDE-5i
The advent of PDE-5i has certainly increased
interest in post-RP ED, and PDE-5 responsiveness has been
incorporated into the definition of successful ED
outcome after RP. The post-RP patient remains one of the
most refractory groups of PDE-5i patients [83_85] with
intercourse success rates of approximately 40% in
placebo controlled studies. An intact cavernous nerve-SM
relationship is optimal for maximum PDE-5 efficacy. Any
decrease in the number of nerves or SM responsiveness
decreases the efficacy of the PDE-5i. In addition, the
responsiveness to PDE-5i after RP is clearly dependent
on the time from surgery with the maximum recovery
taking place at 18_24 months [86], within the time frame
expected for nerve recovery [87]. That being the case,
what rationale is there for the use of sildenafil in penile
rehabilitation? Indeed the early use of chronic
PDE-5i post-RP has been questioned [88].
In a randomized placebo controlled study of 76 men
after BNSRRP [84] serial NPT (1, 4, 8 and 12 months)
and recording of unassisted erectile function
satisfactory for vaginal penetration at one year, in men who took
50 or 100 mg of sildenafil nightly for 9 months
postoperatively was performed. These researchers found a 7
fold improvement of normalization of erectile function in
the treatment group over placebo at one year. NPT was
better in the treatment group with most of the benefit
demonstrated in the first 4 months with a profound loss
of Rigiscan detected NPT at one month
postoperatively (Table 6) [55].
The purported mechanisms to explain these results
were: reduction in post operative corporal hypoxia,
enhanced endothelial function and possible neurotropic
mechanisms. Montorsi [89] has shown in a placebo
controlled study that the use of sidenafil citrate (SC) taken
nightly enhances NPT. It is possible that the nightly SC
enhances corporal oxygenation to a "sub-erectile" state,
much like PGE-1 was shown to enhance corporal
StO2 . The administration of nightly SC decreases penile
fibrosis after RP [63]. In patients in whom vascular
endothelial function is impaired by conditions such as aging,
diabetes, hypertension, or hyperlipidemia, administration
of SC improved endothelium-dependent vasodilation
[90_92]. As eNOS is important in the maintenance of erections,
it is possible that SC is potentiating the pro-erectogenic
effect of eNOS. In rats treated within 24 h of stroke,
SC increased neurogenesis and reduced neurological
deficits [93], suggesting the capacity to promote recovery
of nerve function. SC may enhance cavernous nerve
regeneration. Comparable studies have not been carried
out with the other PDE-5i nor has a larger study been
done. It is recognized that there are difficulties to
carrying out such a large placebo controlled studies.
11 Post operative steroid administration
In an attempt to improve ED outcomes by modifying the acute post-operative inflammatory response, a
6-day course of methylprenisolone was used in a placebo
controlled randomized study of 70 men undergoing BNSRRP
[94]. The medication was started 16_22 h after surgery.
As can be seen in Tables 7_8, at 3 months there was an
statistically significant advantage to the placebo group at
3 months that disappeared by 6 months. At 12 months
no differences were seen in SHIM scores or in positive
responses to the question "Over the past 4 weeks, when
you attempted sexual intercourse, how often was it
satisfactory for you?". Postoperative complication or
continence rates were not affected by the steroid
administration. According to the authors, it is possible that the
timing, short course of administration and low dose may
be the reason for the negative findings. A similar study
was done with the intra-operative local administration of
bethamethasone on the area of the NVB in 60 men [95].
Using similar outcome instruments, no difference in
postoperative sexual function was seen and there was no
increase in postoperative complications.
12 Neuroimmunophilin ligands
Neuroimmunophilin ligands are orally bioavailable
small molecules that act like growth factors and provide
neuroprotection and neuroregeneration. In
vitro they promote neurite extension in culture and protect neurons
from acute injury. In animal model studies they were
found to be neuroprotective during neurotoxic injury and
neuroregenerative after nerve crush injury. GPI 1485
(Guilford Pharmaceuticals Inc., MD, USA), a cleavage
product from cyclosporine, was used as a
neuroprotective agent after efficacy was shown in a rat cavernous
nerve crush injury model. It was tested in humans with
Parkinson's disease and found to be well tolerated and
safe. Between September 2003 and February 2005, a
6-month, phase 3, placebo controlled multiple fixed dose
(400 mg and 1 000 mg) trial was undertaken to evaluate
the efficacy of GPI 1485. The primary endpoint was
the erectile function domain of the IIEF at 6 months. The
study group was men undergoing BNSRRP with normal preoperative erectile function at major centers excellence
for prostate cancer surgery. There was a primary
analysis in the 40 _59 year old men (n = 182) and a secondary
analysis in the 60_69 year old men (n = 45). Data
captured were IIEF Questionnaire approximately 3, 4, 5, 6,
7, 8, 9, 10, 11, and 12 months post-surgery, health
related quality of life, Health related quality of life (HRQOL),
Questionnaires (Sexual Function-12 [SF-12] and the
UCLA Prostate Cancer Index Short Form) approximately
3, 6, 9, and 12 months post-surgery, PDE-5i use and
study drug compliance. PDE-5i were the only erectogenic
aids permitted throughout the study. Their use has been
shown to impact recovery rates, varied between sites
and was therefore recorded as a confounding variable.
Eighty-nine percent of men completed the study. The
results at 6 months were disappointing. There was a
profound decrease from baseline in all domains of the
IIEF at three and six months. There was no difference
between the treatment groups and placebo in the 40_59
years old group (Table 9) [37]. The treatment arm in the
older age group showed a decrease over placebo in EF
domain at 6 months though the numbers were small and the
difference was not significant (Figure 5). This trial though
not demonstrating a short term neuroprotective benefit
form the neuroimmunophilin ligand perhaps did not
follow the outcome long enough. There are currently
ongoing trials with other neuroprotective agents.
13 Conclusion
ED is very common subsequent to surgery for
prostate cancer. Factors that affect the development of the
ED are varied and include pre-surgery erectile function,
age of the patient, stage of the cancer, and the
nerve-sparing nature of the surgery. Immediate causes of the
dysfunction appear to be related to the status of the local
nerve followed by secondary SM injury and corporal
fibrosis.
The fact that prostate cancer is being detected
earlier and in younger men, and that RP provides for an
extended survival time, means that patients will be living
with the consequences of surgery (and other treatments)
such as poor erectile function for a long period of time.
It is important to provide these men with therapies that
can restore erectile and sexual function as quickly as
possible. Contemporary studies suggest that early
initiation of local treatments such as PGE-1 or PDE inhibitor
(PDE-i), may return the subject to long term spontaneity,
or at least to responsiveness to oral therapies. The
optimal penile rehabilitation strategy has not yet been
devised but may encompass both PGE-1 and
vasodilatation with PDE-5i. As the penile atrophy and fibrotic
changes penis occur in the first three months after RP
early postoperative early intervention is crucial. It is
important to present and explain these various options to
the patient prior to surgery so that he can make an
informed decision as to what type of therapy is most
appropriate and desirable for him. More large scale
placebo or active control studies are needed to elucidate the
best postoperative strategy.
References
1 Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics CA
Cancer J Clin 1999; 49: 8_31.
2 Burkhardt JH, Litwin MS, Rose CM, Correa RJ, Sunshine JH,
Hogan C, et al. Comparing the costs of radiation therapy and
radical prostatectomy for the initial treatment of early-stage
prostate cancer. J Clin Oncol 2002; 20: 2869_75.
3 Jochen W, Salomon G, Perrotte P. Prevalence of erectile
dysfunction in a prostate cancer screening population. American
Urological Association (AUA) 2007 Annual Meeting. May
19_24, 2007, Anaheim, CA, USA. J Urol 2007; 177 (4 Suppl):
Abstract 1035.
4 Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland
FD, et al. 5-year urinary and sexual outcomes after radical
prostatectomy: results from the prostate cancer outcomes study.
J Urol 2005; 173: 1701_5.
5 Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported
urinary continence and sexual function after anatomic radical
prostatectomy. Urology 2000; 55: 58_61.
6 Kao TC, Cruess DF, Garner D, Foley J, Seay T, Friedrichs P,
et al. Multicenter patient self-reporting questionnaire on impotence,
incontinence and stricture after radical prostatectomy. J Urol
2000; 163: 858_64.
7 Jonler M, Ritter MA, Brinkmann R, Messing EM, Rhodes PR,
Bruskewitz RC, et al. Sequelae of definitive radiation therapy for
prostate cancer localized to the pelvis. Urology 1994; 44: 876_82.
8 Jonler M, Nielsen OS, Wolf H. Urinary symptoms, potency, and
quality of life in patients with localized prostate cancer followed
up with deferred treatment. Urology 1998; 52: 1055_62;
discussion 1063.
9 Kendirci M, Bejma J, Hellstrom WJ. Update on erectile dysfunction
in prostate cancer patients. Curr Opin Urol 2006; 16: 186_95.
10 Walsh PC, Donker PJ. Impotence following radical prostatectomy:
insight into etiology and prevention. 1982. J Urol 2002; 167(2 Pt
2): 1005_10.
11 Young HH. The early diagnosis and radical cure of carcinoma of
the prostate. Being a study of 40 cases and presentation of a
radical operation which was carried out in four cases. 1905. J
Urol 2002; 168: 914_21.
12 Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function
following radical prostatectomy: influence of preservation of
neurovascular bundles. J Urol 1991; 145: 998_1002.
13 Impotence. NIH Consens Statement 1992; 10: 1.
14 Walsh PC, Mostwin JL. Radical prostatectomy and
cystoprostatectomy with preservation of potency. Results using a new
nerve-sparing technique. Br J Urol 1984; 56: 694_7.
15 Fleischmann J D, Catalona W J. Endocrine therapy for bladder
outlet obstruction from carcinoma of the prostate. J Urol
1985;134: 498_500.
16 Pontes J E, Huben R, Wolf R. Sexual function after radical
prostatectomy. Prostate 1986; 8: 123_6.
17 Narayan P. Nerve sparing and continence preservation during
radical prostatectomy. Urol Int 1991; 46: 266_74.
18 Loughlin KR, O'Leary, MP. Re: Oral androgens in the treatment
of hypogonadal impotent men. J Urol. 1995; 153: 1645.
19 Krupski TL, Saigal CS, Litwin MS. Variation in continence and
potency by definition. J Urol 2003; 170(4 Pt 1): 1291_4.
20 Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA,
Eley JW, et al. Urinary and sexual function after radical
prostatectomy for clinically localized prostate cancer: the Prostate
Cancer Outcomes Study. JAMA. 2000; 283: 354_60.
21 Ayajiki K, Toda N, Okamura T. Nitroxidergic (nitrergic) nerve
and erectile dysfunction. Nippon Yakurigaku Zasshi 2002;
119:21_8.
22 Williams BA, Liu C, Deyoung L, Brock GB, Sims SM. Regulation
of intracellular Ca2+ release in corpus cavernosum smooth muscle:
synergism between nitric oxide and cGMP. Am J Physiol Cell
Physiol 2005; 288: C650_8.
23 Ruiz Rubio JL, Hernandez M, Rivera de los Arcos L, Martinez
AC, Garcia-Sacristan A, Prieto D. Mechanisms of prostaglandin
E1-induced relaxation in penile resistance arteries. J Urol
2004;171 (2 Pt 1): 968_73.
24 Lin JS, Lin YM, Jou YC, Cheng JT. Role of cyclic adenosine
monophosphate in prostaglandin E1-induced penile erection in
rabbits. Eur Urol 1995; 28: 259_65.
25 Lue TF, Takamura T, Schmidt RA, Tanagho EA. Potential
preservation of potency after radical prostatectomy. Urology
1983; 22: 165_7.
26 Quinlan DM, Nelson RJ, Walsh PC. Cavernous nerve grafts restore
erectile function in denervated rats. J Urol 1991; 145: 380_3.
27 Carrier S, Zvara P, Nunes L, Kour NW, Rehman J, Lue TF.
Regeneration of nitric oxide synthase-containing nerves after cavernous
nerve neurotomy in the rat. J Urol 1995; 153: 1722_7.
28 Klein LT, Miller MI, Buttyan R, Raffo AJ, Burchard M, Devris G,
et al. Apoptosis in the rat penis after penile denervation. J Urol
1997; 158: 626_30.
29 Rosenberg ME, Dvergsten J, Correa-Rotter R. Clusterin: an
enigmatic protein recruited by diverse stimuli. J Lab Clin Med
1993;121: 205_14.
30 Gontero P, Galzerano M, Bartoletti R, Magnani C, Tizzani A,
Frea B, et al. New insights into the pathogenesis of penile
shortening after radical prostatectomy and the role of postoperative
sexual function. J Urol 2007; 178: 602_7.
31 McCullough AR, Fenig D, Robbins D, Brassil D, Goodwin B. A 6-
month interim analysis of the effect of nightly intraurethral
alprostadil vs. sildenafil on penile morphometrics after nerve
spearing radical prostatectomy. American Urological
Association Meeting 2007, May 19_24, Anaheim, CA, USA. J Urol
2007; 177 (4 Suppl): Abstract 1173.
32 Fraiman MC, Lepor H, McCullough AR. Changes in penile
morphometrics in men with erectile dysfunction after
nerve-sparing radical retropubic prostatectomy. Mol Urol 1999;
3:109_15.
33 User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT.
Penile weight and cell subtype specific changes in a post-radical
prostatectomy model of erectile dysfunction. J Urol 2003;
169:1175_9.
34 Ciancio SJ, Kim ED. Penile fibrotic changes after radical
retropubic prostatectomy. BJU Int 2000; 85: 101_6.
35 Burnett AL, Becker RE. Immunophilin ligands promote penile
neurogenesis and erection recovery after cavernous nerve injury.
J Urol 2004; 171: 495_500.
36 Burnett AL, Lue TF. Neuromodulatory therapy to improve
erectile function recovery outcomes after pelvic surgery. J Urol 2006;
176: 882_7.
37 Burnett A, McCullough A, Smith J, Montie J, Walsh PC, Steiner
J. Neuromodulation to preserve erectile function after radical
prostatectomy: results from the GPI1485 neuroimmunophilin
ligand clinical trial. American Urological Association Meeting
2007, May 19_24, Anaheim, CA, USA. J Urol 2007; 177 (4
Suppl): Abstract 1162.
38 Ferrini MG, Davila HH, Kovanecz I, Sanchez SP,
Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of
corporal smooth muscle that occurs after bilateral cavernosal
nerve resection in the rat. Urology 2006; 68: 429_35.
39 Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer
J. Rationale for phosphodiesterase 5 inhibitor use post-radical
prostatectomy: experimental and clinical review. Int J Impot
Res 2007 Aug 2; [Epub ahead of print].
40 Vignozzi L, Filippi S, Morelli A, Ambrosini S, Luconi M, Vannelli
GB, et al. Effect of chronic tadalafil administration on penile
hypoxia induces by cavernous neurotomy in the rat. J Sex Med
2006; 3: 419_31.
41 Podlasek CA, Meroz CL, Tang Y, McKenna KE, McVary KT.
Regulation of cavernous nerve injury-induced apoptosis by sonic
hedgehog. Biol Reprod 2007; 76: 19_28.
42 Podlasek CA, Zelner DJ, Jiang HB, Tang Y, Houston J, McKenna
KE, et al. Sonic hedgehog cascade is required for penile postnatal
morphogenesis, differentiation, and adult homeostasis. Biol
Reprod 2003; 68: 423_38.
43 Podlasek CA, Zelner DJ, Harris JD, Meroz CL, Tang Y, McKenna
KE, et al. Altered Sonic hedgehog signaling is associated with
morphological abnormalities in the penis of the BB/WOR
diabetic rat. Biol Reprod 2003; 69: 816_27.
44 Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB,
McKinlay JB. Modifiable risk factors and erectile dysfunction:
can lifestyle changes modify risk? Urology 2000; 56: 302_6.
45 Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino
PT. Factors predicting recovery of erections after radical
prostatectomy. J Urol 2000; 164: 1929_34.
46 McCullough A, Woo K, Telegrafi S, Lepor H. Is sildenafil failure
in men after radical retropubic prostatectomy (RRP) due to
arterial disease? Penile duplex Doppler findings in 174 men after
RRP. Int J Impot Res 2002; 14: 462_5.
47 Gralnek D, Wessells H, Cui H, Dalkin BL. Differences in sexual
function and quality of life after nerve sparing and nonnerve
sparing radical retropubic prostatectomy. J Urol 2000; 163:
1166_9; discussion 1169_70.
48 Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona
WJ. Potency, continence and complications in 3,477 consecutive
radical retropubic prostatectomies. J Urol 2004; 172 (6 Pt
1): 2227_31.
49 Lee SA, Sung KH, Han JH, Han BK,Yu JI, Jeong SJ,
et al. Significance of neurovascular bundle formation observed on
preoperative magnetic resonance imaging regarding postoperative
erectile function after nerve-sparing radical retropubic prostatectomy.
Urology 2007; 69: 510_4.
50 Bannowsky A, Schulze H, van der Horst C, Stubinger JH, Portillo
FJ, Junemann KP. Erectile function after nerve-sparing radical
prostatectomy. Nocturnal early erection as a parameter of
postoperative organic erectile integrity. Urologe A 2005; 44: 521_6.
51 Kawanishi Y, Lee KS, Kimura K, Kojima K, Yamamoto A, Numata
A. Effect of radical retropubic prostatectomy on erectile function,
evaluated before and after surgery using colour Doppler
ultrasonography and nocturnal penile tumescence monitoring. BJU
Int 2001; 88: 244_7.
52 Lerner SE, Richards SL, Benet AE, Kahan NZ, Fleischmann JD,
Melman A. Detailed evaluation of sexual function after radical
prostatectomy: is patient satisfaction correlated with the quality
of erections?. Prog Urol 1996; 6: 552_7. French.
53 Fraiman M, Lepor H, McCullough A. Nocturnal penile
tumescence activity in 81 patients presenting with erectile
dysfunction after nerve sparing radical prostatectomy. American
Urological Association 94th Annual Meeting. Dallas, TX, USA. May
1_6, 1999. J Urol 1999; 161: 179 (Abstract).
54 Levine LM, McCullough AR, Padma-Nathan H. Longitudinal
randomized placebo controlled study of the return of nocturnal
erections after nerve sparing radical prostatectomy in men treated
with nightly sildenafil citrate. American Urological Association
Annual Meeting 2004. May 8_13, San Francisco, CA, USA. J
Urol 1004; 171: 231 (Abstract 875)
55 Padma-Nathan H, McCullough AR, Giuliano F, Toler SM,
Wohlhuter C, Shpilsky AB. Postoperative nightly
administration of sildenafil citrate significantly improves the return of
normal spontaneous erectile function after bilateral
nerve-sparing radical prostatectomy. American Urological Association
Annual Meeting 2003. Chicago, IL, USA. April 26_May 1. J Urol
2003; 169 (4 Suppl): Abstract 1402.
56 Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hyun JS,
Champion HC, et al. Cavernous neurotomy causes hypoxia and
fibrosis in rat corpus cavernosum. J Androl 2003; 24: 239_45.
57 Moreland RB. Is there a role of hypoxemia in penile fibrosis: a
viewpoint presented to the Society for the Study of Impotence.
Int J Impot Res 1998; 10: 113_20.
58 Hu WL, Hu LQ, Song J, Li SW, Zheng XM, Cheng B, Tian BC.
Fibrosis of corpus cavernosum in animals following cavernous
nerve ablation. Asian J Androl 2004; 6: 111_6.
59 Moreland RB, Traish A, McMillin MA, Smith B, Goldstein I,
Saenz de Tejada I. PGE1 suppresses the induction of collagen
synthesis by transforming growth factor-beta 1 in human corpus
cavernosum smooth muscle. J Urol 1995; 153 (3 Pt 1): 826_34.
60 Kim NN, Kim JJ, Hypolite J, Garcia-Diaz JF, Broderick GA,
Tornheim K, et al. Altered contractility of rabbit penile corpus
cavernosum smooth muscle by hypoxia. J Urol 1996; 155: 772_8.
61 Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, Saenz de
Tejada I, et al. Oxygen tension regulates the nitric oxide pathway.
Physiological role in penile erection. J Clin Invest 1993;
91:437_42.
62 Padmanaban P, McCullough AR. The relationship between post
radical retropubic prostatectomy (RRP) erectile dysfunction (ED)
and corporal oxygen saturation (StO2) in the flaccid penis. J
Androl 2007; 28: 223_8.
63 Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves
intracorporeal smooth muscle after radical retropubic prostatectomy.
J Urol 2004; 171 (2 Pt 1): 771_4.
64 Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L,
Barbieri L, et al. Recovery of spontaneous erectile function
after nerve-sparing radical retropubic prostatectomy with and
without early intracavernous injections of alprostadil: results of
a prospective, randomized trial. J Urol 1997; 158: 1408_10.
65 Bosshardt RJ, Farwerk R, Sikora R, Sohn M, Jakse G. Objective
measurement of the effectiveness, therapeutic success and dynamic
mechanisms of the vacuum device. Br J Urol 1995; 75:786_91.
66 Broderick GA, McGahan JP, Stone AR, White RD. The
hemodynamics of vacuum constriction erections: assessment by color
Doppler ultrasound. J Urol 1992; 147: 57_61.
67 Diederichs W, Stief CG, Benard F, Bosch R, Lue TF, Tanagho
EA. The sympathetic role as an antagonist of erection. Urol Res
1991; 19: 123_6.
68 Raina R, Agarwal A, Ausmundson S, Lakin M, Nandipati KC,
Montague DK, et al. Early use of vacuum constriction device
following radical prostatectomy facilitates early sexual activity
and potentially earlier return of erectile function. Int J Impot
Res 2006; 18: 77_81.
69 Moon DG, Lee DS, Kim JJ. Altered contractile response of penis
under hypoxia with metabolic acidosis. Int J Impot Res 1999;
11:265_71.
70 Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of
action of sildenafil for the treatment of erectile dysfunction. Br
J Clin Pharmacol 2002; 53 (Suppl 1): 61S_65S.
71 Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination
therapy: intracavernosal injections and sildenafil following
radical prostatectomy increases sexual activity and the return of
natural erections. Int J Impot Res 2006; 18: 446_51.
72 Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use
of an erectogenic pharmacotherapy regimen following radical
prostatectomy improves recovery of spontaneous erectile
function. J Sex Med 2005; 2: 532_40; discussion 540_2.
73 Gontero P, Fontana F, Bagnasacco A, Panella M, Kocjancic E,
Pretti G, et al. Is there an optimal time for intracavernous
prostaglandin E1 rehabilitation following nonnerve sparing radical
prostatectomy? Results from a hemodynamic prospective study.
J Urol 2003; 169: 2166_9.
74 Costabile RA, Spevak M, Fishman IJ, Govier FE, Hellstrom WJ,
Shabsigh R, et al. Efficacy and safety of transurethral alprostadil
in patients with erectile dysfunction following radical
prostatectomy. J Urol 1998; 160: 1325_8.
75 Raina R, Agarwal A, Ausmundson S, Mansour D, Zippe CD.
Long-term efficacy and compliance of MUSE for erectile dysfunction
following radical prostatectomy: SHIM (IIEF-5) analysis. Int J
Impot Res 2005; 17: 86_90.
76 Raina R, Agarwal A, Nandipati KC, Zippe CD. Interim analysis of
the early use of MUSE following radical prostatectomy (RP) to
facilitate early sexual activity and return of spontaneous erectile
function. American Urological Association Meeting 2005, May
21_26, San Antonio, TX, USA. J Urol 2005; 173 (4
Suppl): Abstract 737.
77 Snider WD, Zhou FQ, Zhong J, Markus A. Signaling the pathway
to regeneration. Neuron 2002; 35: 13_6.
78 McCoy GB, Barry JM, Lieberman SF, Pearse HD, Wicklund R.
Treatment of obliterated membranous and bulbous urethras by
direct vision internal urethrotomy. J Trauma 1987; 27: 883_6.
79 Chierzi S, Ratto GM, Verma P, Fawcett JW. The ability of axons
to regenerate their growth cones depends on axonal type and
age, and is regulated by calcium, cAMP and ERK. Eur J Neurosci
2005; 21: 2051_62.
80 Jiang F, Yang L, Cai X, Cyriac J, Shechter I, Wang Z. Farnesyl
diphosphate synthase is abundantly expressed and regulated by
androgen in rat prostatic epithelial cells. J Steroid Biochem Mol
Biol 2001; 78: 123_30.
81 Kogawa T, Yanagiya H, Takashima T, Higashino I, Kudo T,
Suzuki T, et al. Clinical evaluation of the long-term treatment
with chlormadinone acetate in patients with benign prostatic
hypertrophy. Hinyokika Kiyo 1993; 39: 281_7.
82 Padmanaban P, McCullough AR. The effect of
prostaglandin E-1 (PGE-1) urethral suppository (MUSE) and injections on
corporal oxygen saturation (StO2) in men with erectile dysfunction
(ED). Amercian Society of Andrology Meeting 2006, April
8_11, Chicago IL, USA. J Androl 2006; 27: Abstract.
83 Lowentritt BH, Scardino PT, Miles BJ, Orejuela FJ, Schatte EC,
Slawin KM, et al. Sildenafil citrate after radical retropubic
prostatectomy. J Urol 1999; 162: 1614_7.
84 Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M,
et al. Safety and efficacy of vardenafil for the treatment of men
with erectile dysfunction after radical retropubic prostatectomy.
J Urol 2003; 170 (4 Pt 1): 1278_83.
85 Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G,
Ahuja S, et al. Tadalafil in the treatment of erectile dysfunction
following bilateral nerve sparing radical retropubic prostatectomy:
a randomized, double-blind, placebo controlled trial. J Urol
2004;172: 1036_41. Erratum in: J Urol 2005; 173: 664.
86 Hong EK, Lepor H, McCullough AR. Time dependent patient
satisfaction with sildenafil for erectile dysfunction (ED) after
nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot
Res 1999; 11 (Suppl 1): S15_22.
87 Walsh PC. Patient-reported urinary continence and sexual
function after anatomic radical prostatectomy. J Urol 2000; 164:242.
88 Gontero P, Kirby R. Proerectile pharmacological prophylaxis
following nerve-sparing radical prostatectomy (NSRP). Prostate
Cancer Prostatic Dis 2004; 7: 223_6.
89 Montorsi F, Maga T, Strambi LF, Salonia A, Barbieri L, Scattoni
V, et al. Sildenafil taken at bedtime significantly increases
nocturnal erections: results of a placebo-controlled study. Urology
2000; 56: 906_11.
90 Katz SD. Potential role of type 5 phosphodiesterase inhibition
in the treatment of congestive heart failure. Congest Heart Fail
2003; 9: 9_15.
91 Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S.
Acute type 5 phosphodiesterase inhibition with sildenafil
enhances flow-mediated vasodilation in patients with chronic heart
failure. J Am Coll Cardiol 2000; 36: 845_51.
92 Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and
prolonged effects of sildenafil on brachial artery flow-mediated
dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336_9.
93 Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M,
et al. Sildenafil (Viagra) induces neurogenesis and promotes functional
recovery after stroke in rats. Stroke 2002; 33: 2675_80.
94 Parsons JK, Marschke P, Maples P, WAlsh PC. Effect of
methylprednisolone on return of sexual function after nerve-sparing
radical retropubic prostatectomy. Urology 2004; 64: 987_90.
95 Deliveliotis C, Delis A, Papatsoris A, Antoniou N, Varkarakis IM.
Local steroid application during nerve-sparing radical retropubic
prostatectomy. BJU Int 2005; 96: 533_5.
|